Published Date: 02 Mar 2023
A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.
Read Full NewsIrreversible nerve damage to the lower limbs is a common side effect of chemotherapy, yet up to 50% of patients are missing out on vital foot care that could significantly ease their symptoms, according to new research from ...
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate ...
Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in screening, surgery and personalized treatment are helping more patients live longer.
1.
Congresswoman has cancer; the IRS is suing a controversial doctor; and caffeine and teenagers.
2.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.
5.
Train Eyes so Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Stroke
1.
Unlocking the Immune Arsenal: A Revolution in Cancer Treatment
2.
Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia
3.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
4.
Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis
5.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation